Main Session
Sep
29
PQA 06 - Radiation and Cancer Biology, Health Care Access and Engagement
3085 - Impact of KRAS Mutation Status on Long-Term Oncological Outcomes in Unresectable Stage III NSCLC Treated with Chemoradiation with or without Immunotherapy
Presenter(s)

Ritesh Kumar, MD - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ